RET-MAP: An International Multicenter Study on Clinicobiologic Features and Treatment Response in Patients With Lung Cancer Harboring a RET Fusion.

Autor:	Aldea M; Department of Medical Oncology, International Center for Thoracic Cancers (CICT), Gustave Roussy, Villejuif, France; Paris-Saclay University, Kremlin-Bicêtre, France., Marinello A; Department of Medical Oncology, International Center for Thoracic Cancers (CICT), Gustave Roussy, Villejuif, France; Department of Medical Oncology, Humanitas Research Hospital, Milan, Italy., Duruisseaux M; Respiratory Department and Early Phase, Louis Pradel Hospital, Hospices Civils de Lyon; Cancer Research Center of Lyon (CRCL), INSERM 1052, CNRS 5286; Univ Lyon, Claude Bernard Lyon 1 University, Lyon, France., Zrafi W; Department of Biostatistics and Bioinformatics, Gustave Roussy, Villejuif, France., Conci N; Department of Medical Oncology, Scientific Institute for Research, Hospitalization and Healthcare (IRCCS) University Hospital of Bologna, Bologna, Italy., Massa G; Department of Medical Oncology, National Cancer Institut, Milan, Italy., Metro G; Department of Medical Oncology, Santa Maria della Misericordia Hospital, Perugia, Italy., Monnet I; Pneumology and Thoracic Oncology Department, Intercommunal Hospital of Creteil (CHI), Creteil, France., Gomez Iranzo P; Department of Medical Oncology, Vall d'Hebron University Hospital, Barcelona, Spain., Tabbo F; Department of Oncology, University of Turin, San Luigi Hospital, Orbassano, Italy., Bria E; Department of Medical Oncology, Comprehensive Cancer Center, IRCCS Agostino Gemelli, Catholic University of the Sacred Heart, Rome, Italy., Guisier F; Department of Medical Oncology, Rouen University Hospital, Rouen, France., Vasseur D; Department of Medical Biology and Pathology, Gustave Roussy, Villejuif, France., Lindsay CR; Department of Medical Oncology, The Christie NHS Foundation Trust, Manchester, United Kingdom., Ponce-Aix S; Department of Medical Oncology, University Hospital October 12, Madrid, Spain., Cousin S; Department of Medical Oncology, Bergonié Institut, Bordeaux, France., Citarella F; Department of Medical Oncology, Campus Biomedico, Rome, Italy., Fallet V; Department of Pneumology and Thoracic Oncology, Tenon Hospital, Assistance Publique Hôpitaux de Paris and GRC 4, Theranoscan, Sorbonne Université, Paris, France., Minatta JN; Department of Medical Oncology, Hospital Italiano, Buenos Aires, Argentina., Eisert A; Department of Medical Oncology, University Hospital of Cologne, Cologne, Germany., de Saint Basile H; Department of Medical Oncology, European Hospital Georges Pompidou, Paris, France., Audigier-Valette C; Department of Medical Oncology, Hospital Sainte Musse, Toulon, France., Mezquita L; Medical Oncology Department, Hospital Clinic of Barcelona, Barcelona, Spain; Laboratory of Translational Genomics and Targeted Therapies in Solid Tumors, Institut D'Investigacions Biomediques August Pi i Sunyer (IDIBAPS), Barcelona, Spain., Calles A; Department of Medical Oncology, Hospital General Universitario Gregorio Marañón, Madrid, Spain., Mountzios G; 4th Oncology Department and Clinical Trials Unit, Henry Dunant Hospital Center, Athens, Greece., Tagliamento M; Department of Internal Medicine and Medical Specialties, University of Genova, Genova, Italy., Remon Masip J; Department of Medical Oncology, Centro Integral Oncológico Clara Campal (HM-CIOCC), Hospital HM Delfos, HM Hospitales, Barcelona, Spain., Raimbourg J; Department of Medical Oncology, Institut de Cancérologie de l'Ouest, St Herblain, France., Terrisse S; Department of Medical Oncology, Saint Louis Hospital, Paris, France., Russo A; Department of Medical Oncology, Papardo Hospital, Messina, Italy., Cortinovis D; Department of Medical Oncology, San Gerardo Hospital, Monza, Italy., Rochigneux P; Department of Medical Oncology, Paoli-Calmettes Institute, Marseille, France., Pinato DJ; Department of Surgery and Cancer, Imperial College London, Hammersmith Campus, London, United Kingdom; Division of Oncology, Department of Translational Medicine, University of Piemonte Orientale, Novara, Italy., Cortellini A; Department of Medical Oncology, Campus Biomedico, Rome, Italy., Leonce C; Department of Molecular Pathology, Louis-Pradel Hospital, Lyon, France., Gazzah A; Department of Drug Development Department, International Center for Thoracic Cancers (CICT), Gustave Roussy, Villejuif, France., Ghigna MR; Department of Pathology, International Center for Thoracic Cancers (CICT), Gustave Roussy, Villejuif, France., Ferrara R; Department of Medical Oncology, National Cancer Institut, Milan, Italy., Dall'Olio FG; Department of Biostatistics and Bioinformatics, Gustave Roussy, Villejuif, France., Passiglia F; Department of Oncology, University of Turin, San Luigi Hospital, Orbassano, Italy., Ludovini V; Department of Medical Oncology, Santa Maria della Misericordia Hospital, Perugia, Italy., Barlesi F; Department of Medical Oncology, International Center for Thoracic Cancers (CICT), Gustave Roussy, Villejuif, France; Paris-Saclay University, Kremlin-Bicêtre, France., Felip E; Department of Medical Oncology, Vall d'Hebron University Hospital, Barcelona, Spain., Planchard D; Department of Medical Oncology, International Center for Thoracic Cancers (CICT), Gustave Roussy, Villejuif, France., Besse B; Department of Medical Oncology, International Center for Thoracic Cancers (CICT), Gustave Roussy, Villejuif, France; Paris-Saclay University, Kremlin-Bicêtre, France. Electronic address: benjamin.besse@gustaveroussy.fr.
Jazyk:	angličtina
Zdroj:	Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer [J Thorac Oncol] 2023 May; Vol. 18 (5), pp. 576-586. Date of Electronic Publication: 2023 Jan 13.
DOI:	10.1016/j.jtho.2022.12.018
Abstrakt:	Introduction: Nearly 1% to 2% of NSCLCs harbor RET fusions. Characterization of this rare population is still incomplete. Methods: This retrospective multicenter study included patients with any-stage RET positive (RET+) NSCLC from 31 cancer centers. Molecular profiling included DNA/RNA sequencing or fluorescence in situ hybridization analyses. Clinicobiological features and treatment outcomes (per investigator) with surgery, chemotherapy (CT), immune checkpoint blockers (ICBs), CT-ICB, multityrosine kinase inhibitors, and RET inhibitors (RETis) were evaluated. Results: For 218 patients included between February 2012 and April 2022, median age was 63 years, 56% were females, 93% had adenocarcinoma, and 41% were smokers. The most frequent fusion partner was KIF5B (72%). Median tumor mutational burden was 2.5 (range: 1-4) mutations per megabase, and median programmed death-ligand 1 expression was 10% (range: 0%-55%). The most common metastatic sites were the lung (50%), bone (43%), and pleura (40%). Central nervous system metastases were found at diagnosis of advanced NSCLC in 21% of the patients and at last follow-up or death in 31%. Overall response rate and median progression-free survival were 55% and 8.7 months with platinum doublet, 26% and 3.6 months with single-agent CT, 46% and 9.6 months with CT-ICB, 23% and 3.1 months with ICB, 37% and 3 months with multityrosine kinase inhibitor, and 76% and 16.2 months with RETi, respectively. Median overall survival was longer in patients treated with RETi versus no RETi (50.6 mo [37.7-72.1] versus 16.3 mo [12.7-28.8], p < 0.0001). Conclusions: Patients with RET+ NSCLC have mainly thoracic and bone disease and low tumor mutational burden and programmed death-ligand 1 expression. RETi markedly improved survival, whereas ICB may be active in selected patients. (Copyright © 2023 International Association for the Study of Lung Cancer. Published by Elsevier Inc. All rights reserved.)
Databáze:	MEDLINE
Externí odkaz:	Zobrazit plný text záznamu